ATE333889T1 - Verfahren zur gewinnung von inhibitoren der tirc7-liganden-bindung und verwendungszwecke dafür - Google Patents

Verfahren zur gewinnung von inhibitoren der tirc7-liganden-bindung und verwendungszwecke dafür

Info

Publication number
ATE333889T1
ATE333889T1 AT01992581T AT01992581T ATE333889T1 AT E333889 T1 ATE333889 T1 AT E333889T1 AT 01992581 T AT01992581 T AT 01992581T AT 01992581 T AT01992581 T AT 01992581T AT E333889 T1 ATE333889 T1 AT E333889T1
Authority
AT
Austria
Prior art keywords
obtaining
tirc7
ligand binding
alpha
treatment
Prior art date
Application number
AT01992581T
Other languages
English (en)
Inventor
Nalan Utku
Original Assignee
Genpat77 Pharmacogenetics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genpat77 Pharmacogenetics Ag filed Critical Genpat77 Pharmacogenetics Ag
Application granted granted Critical
Publication of ATE333889T1 publication Critical patent/ATE333889T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT01992581T 2000-10-30 2001-10-29 Verfahren zur gewinnung von inhibitoren der tirc7-liganden-bindung und verwendungszwecke dafür ATE333889T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00123666 2000-10-30

Publications (1)

Publication Number Publication Date
ATE333889T1 true ATE333889T1 (de) 2006-08-15

Family

ID=8170238

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01992581T ATE333889T1 (de) 2000-10-30 2001-10-29 Verfahren zur gewinnung von inhibitoren der tirc7-liganden-bindung und verwendungszwecke dafür

Country Status (9)

Country Link
US (1) US20040072780A1 (de)
EP (1) EP1353687B1 (de)
JP (1) JP2004512371A (de)
AT (1) ATE333889T1 (de)
AU (2) AU2002221775B2 (de)
CA (1) CA2425583A1 (de)
DE (1) DE60121811T2 (de)
ES (1) ES2269505T3 (de)
WO (1) WO2002036149A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050118178A1 (en) * 2001-11-27 2005-06-02 Nalan Utku Use of t-cell immune response cdna7 (tirc7) in angiogenic and anti-angiogenic therapy
US7794715B2 (en) 2001-12-21 2010-09-14 Cellact Pharma Gmbh Anti-TIRC7 antibodies in therapy of inflammatory diseases
CN117561280A (zh) * 2021-04-21 2024-02-13 库尔生物制药有限公司 携带TGF-β的抗原呈递多肽复合物及其使用方法
WO2025111562A1 (en) * 2023-11-22 2025-05-30 Cue Biopharma, Inc. Mhc class ii protein complexes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69332485T2 (de) * 1992-08-11 2003-11-13 The President And Fellows Of Harvard College, Cambridge Immunmodulierende peptide
EP0996726B1 (de) * 1997-08-29 2003-12-10 Brigham And Women's Hospital T-zell-membranprotein (tirc7), davon abgeleitete peptide und antikörper und ihre verwendungen
WO2003025000A2 (en) * 2001-09-17 2003-03-27 Nalan Utku Peptides capable of modulating immune response

Also Published As

Publication number Publication date
EP1353687B1 (de) 2006-07-26
DE60121811T2 (de) 2007-01-18
DE60121811D1 (de) 2006-09-07
JP2004512371A (ja) 2004-04-22
WO2002036149A2 (en) 2002-05-10
CA2425583A1 (en) 2002-05-10
US20040072780A1 (en) 2004-04-15
ES2269505T3 (es) 2007-04-01
AU2002221775B2 (en) 2006-11-23
WO2002036149A3 (en) 2003-08-28
AU2177502A (en) 2002-05-15
EP1353687A2 (de) 2003-10-22

Similar Documents

Publication Publication Date Title
CY1111714T1 (el) Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf).
CY1119353T1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
ATE353974T1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
CY1116107T1 (el) Ενωσεις για χρηση στην αγωγη αυτοανοσων παθησεων, ανοσο-αλλεργικων παθησεων και απορριψης μεταμοσχευσης οργανων ή ιστων
FI20011671A7 (fi) Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö
EP1539228A4 (de) Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
NO20054170L (no) Antistoff mot human IL-21 reseptor og anvendelser derav
ATE319825T1 (de) Verfahren und zusammensetzungen zur immunomodulation
IS6895A (is) Aðferð til að bera kennsl á, einangra og vinna mótefnavaka við ákveðnum sjúkdómsvaldi
IS8432A (is) Mótefni sem bindast viðtaka hvítfrumuboða-4
CY1109868T1 (el) Cd81 πρωτεϊνη υποδοχεας ηπατιτιδας c
FI20011664A7 (fi) Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö
ATE360442T1 (de) Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE602004030541D1 (de) Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexen
EP1499190A4 (de) Verfahren zur behandlung von lebererkrankungen und leberschäden mit wachstumshormon und foxm1b
DE60121811D1 (de) Verfahren zur gewinnung von inhibitoren der tirc7-liganden-bindung und verwendungszwecke dafür
DE60218636D1 (de) Antikörper zur vorbeugung und behandlung von e. coli aeec krankheiten
ATE126599T1 (de) Verfahren zur bestimmung von anti-rns- antikörpern.
DE602006011607D1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
EP2322209A3 (de) Tumorspezifische Oligosaccharid-Epitope und deren Verwendung
ATE406178T1 (de) Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen
DE60109359D1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
CY1105549T1 (el) Καινουργια μεθοδος θεραπειας

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties